NASHVILLE, TN — Ascension Saint Thomas Heart’s structural heart and valve team was the first in Tennessee to implant the ACURATE neo2 Aortic Valve System. The ACURATE neo2 Aortic Valve System is a new generation transcatheter aortic valve replacement (TAVR) device designed to further reduce complication rates, streamline TAVR procedures and expand access to treat patients even with challenging anatomies.
“We are proud to be the first hospital in Tennessee to participate in the ACURATE IDE trial to assess the safety and effectiveness of the ACURATE neo2 Aortic Valve System for patients suffering from severe aortic stenosis,” said Tim Adams, CEO Ascension Saint Thomas. “We are pleased to be part of this important trial to explore this valve as a minimally invasive option for patients at intermediate and greater risk for open heart surgery.”
The ACURATE neo2 Aortic Valve System is a new generation transcatheter aortic valve replacement (TAVR) device building upon the clinically proven features of the ACURATE Aortic Valve Platform, which has been used commercially in Europe and other countries outside of the United States since 2012 in more than 20,000 patients.*
The new self-expanding, supra-annular valve is designed to further reduce complication rates, streamline TAVR procedures and expand access to treat patients even with challenging anatomies. It features a new annular sealing technology designed to minimize paravalvular leakage around the valve, as well as an advanced delivery system for placement accuracy and overall ease of use. In addition, its unique deployment method allows for stable and predictable valve positioning and release.
Ascension Saint Thomas Heart is consistently enrolled in various clinical trials in order to provide the latest in clinical innovations and technologies to our community. For more information on ACURATE neo2 or our other ongoing trials, call 615-222-3944. *The ACURATE neo2 Aortic Valve System is currently an investigational device and not available for sale.
